This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 18, 2013 /PRNewswire/ --
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that the Company will start trading as part of the BEL20 index on the Euronext stock exchange today.
The BEL20 index is a real-time index reflecting the continuous price evolution of the 20 most liquid Belgian shares listed on Euronext Brussels and serves as Blue-chip index for Euronext Brussels. The weight of the index constituents is based on their market capitalization adjusted for free float by using a free float banding system.
ThromboGenics will be included in the BEL20 index as of today.
Patrik De Haes, CEO of ThromboGenics, commented,
"We are very pleased to be now included in the BEL20 index which reflects the tremendous progress ThromboGenics has made since its inception. The inclusion in the index will further increase the Company's access to a broader pool of investors and enhance ThromboGenics'already strong profile as one of the leading biotechnology companies inEurope."
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company's lead product, JETREA
®(ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in
January 2013. In
Europe, it has been approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA
the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon's net sales of JETREA
®. ThromboGenics and Alcon intend to share the costs equally of developing JETREA
® for a number of new vitreoretinal indications.
ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), formerly referred to as TB-403, for the treatment of ophthalmic and oncology indications.